Cullinan Therapeutics, Inc.
CGEM
$9.07
$0.111.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -48.50M | -47.65M | -40.56M | -42.03M | -37.15M |
| Total Depreciation and Amortization | 76.00K | 77.00K | 76.00K | 77.00K | 76.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.06M | 6.12M | 4.50M | 6.81M | 4.73M |
| Change in Net Operating Assets | -1.79M | 4.82M | 1.84M | -1.15M | -5.90M |
| Cash from Operations | -43.16M | -36.63M | -34.14M | -36.29M | -38.25M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 36.81M | 15.96M | 19.88M | -185.11M | 12.96M |
| Cash from Investing | 36.81M | 15.96M | 19.88M | -185.11M | 12.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 1.58M | 1.98M | 265.99M | 1.09M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -656.00K | -3.79M | -- |
| Cash from Financing | -- | 1.58M | 1.33M | 262.20M | 1.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.35M | -19.08M | -12.94M | 40.79M | -24.21M |